Articles related to CARDIOVASCULAR DISEASE (CVD)

A phase 3 trial demonstrates that aficamten improves oxygen utilization during exercise for obstructive HCM patients, indicating its potential to enhance daily functionality and quality of life.

In a phase 2b trial, plozasiran significantly reduced fasting triglyceride levels at 24 weeks in patients with mixed hyperlipidemia, with the 50 mg quarterly dose achieving a mean reduction of 62.4 percentage points. This study highlights the potential of APOC3 inhibition as a therapeutic strategy for lipid management.

This study evaluates the use of statins for primary prevention of cardiovascular diseases in adults aged 75 years and older, demonstrating a significant reduction in CVD incidence without an increase in severe adverse events. These findings provide real-world evidence to guide clinical decision-making in this underrepresented population.

The phase 3 trial of aficamten for symptomatic obstructive hypertrophic cardiomyopathy showed a significant improvement in peak oxygen uptake compared to placebo, with meaningful enhancements in patient-reported outcomes and clinical measures.

Lower baseline testosterone and hormonal imbalances, including low SHBG and DHT levels, are significantly associated with increased all-cause and cardiovascular mortality in aging men.

Cardiac amyloidosis often presents with nonspecific symptoms and requires a high index of suspicion and specialized diagnostic protocols to ensure accurate diagnosis and effective management.